NO339730B1 - Et monomer calicheamicin derivat/anti-CD22 antistoff konjugat samt anvendelse derav. - Google Patents

Et monomer calicheamicin derivat/anti-CD22 antistoff konjugat samt anvendelse derav. Download PDF

Info

Publication number
NO339730B1
NO339730B1 NO20044663A NO20044663A NO339730B1 NO 339730 B1 NO339730 B1 NO 339730B1 NO 20044663 A NO20044663 A NO 20044663A NO 20044663 A NO20044663 A NO 20044663A NO 339730 B1 NO339730 B1 NO 339730B1
Authority
NO
Norway
Prior art keywords
seq
antibody
vincristine
prednisone
cyclophosphamide
Prior art date
Application number
NO20044663A
Other languages
English (en)
Norwegian (no)
Other versions
NO20044663L (no
Inventor
John Mclean Simpson
Arthur Kunz
Justin Keith Moran
Joseph Thomas Rubino
Neera Jain
Eugene Joseph Vidunas
Paul David Robbins
Nishith Merchant
John Dijoseph
Mark Edward Rubben
Nitin Krishnaji Damle
Andrew George Popplewell
Original Assignee
Wyeth Holdings Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO339730(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Co filed Critical Wyeth Holdings Co
Publication of NO20044663L publication Critical patent/NO20044663L/no
Publication of NO339730B1 publication Critical patent/NO339730B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20044663A 2002-05-02 2004-10-28 Et monomer calicheamicin derivat/anti-CD22 antistoff konjugat samt anvendelse derav. NO339730B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02
PCT/US2003/013910 WO2003092623A2 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Publications (2)

Publication Number Publication Date
NO20044663L NO20044663L (no) 2005-01-25
NO339730B1 true NO339730B1 (no) 2017-01-23

Family

ID=29401497

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20044663A NO339730B1 (no) 2002-05-02 2004-10-28 Et monomer calicheamicin derivat/anti-CD22 antistoff konjugat samt anvendelse derav.
NO20161431A NO344509B1 (no) 2002-05-02 2016-09-08 Fremgangsmåte for fremstilling av et preparat omfattende monomer calicheamicin derivat/anti-CD22 antistoff konjugat, preparat fremstilt derved samt anvendelse av preparatet.
NO2017061C NO2017061I1 (no) 2002-05-02 2017-11-21 inotuzumab ozogamicin

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20161431A NO344509B1 (no) 2002-05-02 2016-09-08 Fremgangsmåte for fremstilling av et preparat omfattende monomer calicheamicin derivat/anti-CD22 antistoff konjugat, preparat fremstilt derved samt anvendelse av preparatet.
NO2017061C NO2017061I1 (no) 2002-05-02 2017-11-21 inotuzumab ozogamicin

Country Status (33)

Country Link
US (6) US8153768B2 (OSRAM)
EP (3) EP3127553B1 (OSRAM)
JP (5) JP5153057B2 (OSRAM)
KR (2) KR101062628B1 (OSRAM)
CN (1) CN100482277C (OSRAM)
AU (2) AU2003231293A1 (OSRAM)
BE (1) BE2017C049I2 (OSRAM)
BR (3) BR122019027966B8 (OSRAM)
CA (2) CA2483552A1 (OSRAM)
CR (3) CR7557A (OSRAM)
CY (4) CY1116634T1 (OSRAM)
DK (3) DK2371392T3 (OSRAM)
EC (1) ECSP045445A (OSRAM)
ES (3) ES2545745T3 (OSRAM)
FR (1) FR17C1054I2 (OSRAM)
HU (4) HUE030806T2 (OSRAM)
IL (2) IL164946A (OSRAM)
LT (3) LT1507556T (OSRAM)
LU (1) LUC00044I2 (OSRAM)
MX (1) MXPA04010792A (OSRAM)
NL (1) NL300903I2 (OSRAM)
NO (3) NO339730B1 (OSRAM)
NZ (2) NZ586071A (OSRAM)
PH (2) PH12013501159A1 (OSRAM)
PL (5) PL222725B1 (OSRAM)
PT (3) PT2371392E (OSRAM)
RU (3) RU2422157C3 (OSRAM)
SG (3) SG10201700289RA (OSRAM)
SI (3) SI1507556T1 (OSRAM)
TW (2) TWI379693B (OSRAM)
UA (1) UA88599C2 (OSRAM)
WO (1) WO2003092623A2 (OSRAM)
ZA (2) ZA200409752B (OSRAM)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
JP5470597B2 (ja) * 2004-05-26 2014-04-16 国立大学法人 香川大学 希少糖ｄ−アロースを利用した細胞・組織・臓器保存液及び該液を用いる保存方法
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
BRPI0515113A (pt) * 2004-09-10 2008-07-01 Wyeth Corp anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
BRPI0614826A2 (pt) 2005-08-16 2011-04-19 Synta Pharmaceuticals Corp composições, método para a preparação de liofilizado de uma composição e liofilizado
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
WO2007067602A1 (en) * 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
PL1994055T3 (pl) 2006-03-10 2015-02-27 Wyeth Llc Przeciwciała anty-5T4 i ich zastosowanie
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CA2657248C (en) 2006-07-13 2018-10-30 Wyeth Production of glycoproteins
US8609720B2 (en) 2006-08-21 2013-12-17 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
JP2010506839A (ja) * 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
CA2671457C (en) 2006-12-01 2017-09-26 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
AU2007336897A1 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
CN101687916A (zh) * 2007-01-16 2010-03-31 惠氏公司 通过trem-1的炎症治疗、检测和监控
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
CN102558001B (zh) 2007-05-22 2015-09-23 惠氏有限责任公司 制造酰肼的改良方法
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP2011507897A (ja) * 2007-12-21 2011-03-10 ジェネンテック， インコーポレイテッド リツキシマブ抵抗性関節リウマチ患者の治療
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
KR20100097753A (ko) * 2007-12-26 2010-09-03 바이오테스트 아게 Ｃｄ138 표적성 면역접합체 및 이의 용도
EP2240516B1 (en) * 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
MX341344B (es) * 2007-12-26 2016-08-16 Biotest Ag Agentes dirigidos a cd138 y sus usos.
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
US8591889B2 (en) * 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
FR2930443B1 (fr) * 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
KR20210005318A (ko) 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
KR102444399B1 (ko) * 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
EP2533814A2 (en) * 2010-02-11 2012-12-19 Ablynx N.V. Delivery of immunoglobulin variable domains and constructs thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
US8512679B2 (en) * 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
PL2750768T3 (pl) 2011-08-30 2019-05-31 Astex Pharmaceuticals Inc Formulacje pochodnej decytabiny
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
US20140322758A1 (en) 2011-10-21 2014-10-30 Pfizer Inc. Addition of iron to improve cell culture
KR20140100571A (ko) 2011-12-08 2014-08-14 바이오테스트 아게 Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
KR20150036346A (ko) 2012-07-03 2015-04-07 워싱턴 유니버시티 Tau에 대한 항체
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
NZ630601A (en) 2012-12-21 2017-05-26 Biolliance C V Hydrophilic self-immolative linkers and conjugates thereof
WO2014113203A1 (en) 2013-01-17 2014-07-24 Case Western Reserve University Viral nanoparticle multimers
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014261456B2 (en) * 2013-05-02 2018-10-04 F. Hoffmann-La Roche Ag Combination therapy of an afucosylated CD20 antibody with a CD22 antibody-drug conjugate
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
CN108047287B (zh) * 2013-11-04 2021-04-27 辉瑞大药厂 用于合成加利车霉素衍生物的中间体和方法
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
EP4512889A3 (en) 2014-03-19 2025-05-07 Pfizer Inc. Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
RU2017101662A (ru) 2014-06-20 2018-07-23 Биоэллаенс К.В. Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
JP6731405B2 (ja) 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
BR112017020689A2 (en) 2015-04-07 2018-06-26 Memorial Sloan-Kettering Cancer Center nanoparticulate immunoconjugates
CN107849146A (zh) * 2015-04-21 2018-03-27 艾伯维施特姆森特克斯有限责任公司 卡奇霉素构建体和使用方法
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US10624975B2 (en) 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
HK1254645A1 (zh) 2015-07-02 2019-07-26 Otsuka Pharmaceutical Co., Ltd. 冻乾药物组合物
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3322485B1 (en) * 2015-07-16 2020-07-01 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
JP7001585B2 (ja) 2015-09-23 2022-02-04 ファイザー・インク 細胞および細胞培養の方法
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CN108713026B (zh) 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
EP3440190B1 (en) 2016-04-05 2024-08-28 Pfizer Inc. Cell culture process
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
WO2018017985A1 (en) 2016-07-21 2018-01-25 Case Western Reserve University Plant virus or virus-like particle constructs
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
AU2017354004C1 (en) 2016-11-03 2023-08-31 Case Western Reserve University Melt processed viral nanoparticle constructs
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
WO2018213587A1 (en) 2017-05-17 2018-11-22 Case Western Reserve University Anticancer trail-targeted plant virus particles
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US20200255785A1 (en) 2017-09-15 2020-08-13 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
PT3710485T (pt) * 2018-05-30 2021-05-04 Abbvie Stemcentrx Llc Conjugados de fármaco e anticorpo anti-sez6 e métodos de utilização
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL297931B2 (en) 2018-09-25 2025-03-01 Harpoon Therapeutics Inc DLL3 binding proteins and methods of use
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
US20220073942A1 (en) 2018-12-06 2022-03-10 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
WO2020168090A1 (en) * 2019-02-13 2020-08-20 Geerlings Maurits W Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
JP7684947B2 (ja) 2019-03-19 2025-05-28 フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン 癌の治療のための併用療法
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
US20220288219A1 (en) * 2019-07-08 2022-09-15 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
WO2021113740A1 (en) * 2019-12-04 2021-06-10 The Research Foundation For The State University Of New York Compositions and methods for reducing off-target toxicity of antibody drug conjugates
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
EP4588491A1 (en) * 2022-09-16 2025-07-23 National Institutes for Quantum Science and Technology Production method of intermediate for radiopharmaceutical composition, and purification kit for intermediate for radiopharmaceutical composition
CN120166937A (zh) 2022-10-25 2025-06-17 佩普托米克公司 用于治疗癌症的联合疗法
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
CN121335714A (zh) 2023-06-07 2026-01-13 瓦尔希伯伦私人肿瘤研究基金会 用于治疗癌症的与mek抑制剂的组合疗法
WO2025063789A1 (ko) * 2023-09-21 2025-03-27 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992000311A1 (en) 1990-06-27 1992-01-09 Princeton University Probes for detecting mutant p53
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
CN1172502A (zh) 1994-08-12 1998-02-04 亿万遗传股份有限公司 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE383430T1 (de) 1997-03-20 2008-01-15 Us Gov Health & Human Serv Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
JP4562286B2 (ja) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
EP1210361B1 (en) * 1999-08-17 2004-04-14 Novo Nordisk Health Care AG Stabilisation of freeze-dried cake
EP1336850A1 (de) 1999-10-12 2003-08-20 Connex Gesellschaft zur Optimierung von Forschung und Entwicklung Verbessertes Verfahren zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Also Published As

Publication number Publication date
EP1507556A4 (en) 2009-01-07
NO20044663L (no) 2005-01-25
PL224844B1 (pl) 2017-02-28
US8153768B2 (en) 2012-04-10
LTC2371392I2 (lt) 2019-03-25
PT1507556T (pt) 2016-09-28
PH12013501158A1 (en) 2015-11-09
PH12013501159B1 (en) 2015-12-02
RU2678818C2 (ru) 2019-02-04
JP6872376B2 (ja) 2021-05-19
RU2422157C2 (ru) 2011-06-27
IL164946A0 (en) 2005-12-18
JP5756489B2 (ja) 2015-07-29
CR20120364A (es) 2012-10-05
TWI438010B (zh) 2014-05-21
RU2011108928A (ru) 2012-09-20
NO344509B1 (no) 2020-01-20
BR0309868A (pt) 2005-10-18
NO2017061I1 (no) 2017-11-21
LT1507556T (lt) 2016-10-10
KR20110050753A (ko) 2011-05-16
SI3127553T1 (sl) 2022-02-28
AU2009202609A1 (en) 2009-07-16
IL164946A (en) 2015-06-30
US20040192900A1 (en) 2004-09-30
RU2602878C2 (ru) 2016-11-20
ES2593304T3 (es) 2016-12-07
EP1507556B1 (en) 2016-07-27
US20140235835A1 (en) 2014-08-21
CY1124900T1 (el) 2023-01-05
TW201231089A (en) 2012-08-01
CY2017035I2 (el) 2018-04-04
US8747857B2 (en) 2014-06-10
US8835611B2 (en) 2014-09-16
EP2371392A1 (en) 2011-10-05
BRPI0309868B1 (pt) 2020-04-28
PL228741B1 (pl) 2018-05-30
LTPA2017036I1 (lt) 2017-11-27
KR20050006220A (ko) 2005-01-15
IL230659A (en) 2016-02-29
PL411824A1 (pl) 2015-08-17
JP2005524700A (ja) 2005-08-18
US20120213804A1 (en) 2012-08-23
BR122019027966B1 (pt) 2020-11-17
NL300903I2 (nl) 2018-02-08
AU2003231293A1 (en) 2003-11-17
TW200404005A (en) 2004-03-16
US20160303252A1 (en) 2016-10-20
BRPI0309868B8 (pt) 2021-05-25
LUC00044I2 (OSRAM) 2018-02-26
PL222725B1 (pl) 2016-08-31
ZA201003874B (en) 2019-12-18
JP5441971B2 (ja) 2014-03-12
AU2009202609B2 (en) 2012-07-26
JP2013163678A (ja) 2013-08-22
IL230659A0 (en) 2014-03-31
NZ573563A (en) 2010-10-29
SG10201700289RA (en) 2017-02-27
JP2015061875A (ja) 2015-04-02
SI2371392T1 (sl) 2015-10-30
BE2017C049I2 (OSRAM) 2022-08-09
HUE057124T4 (hu) 2022-02-28
PL224150B1 (pl) 2016-11-30
SI1507556T1 (sl) 2016-10-28
HK1162926A1 (en) 2012-09-07
US20040082764A1 (en) 2004-04-29
JP2012051900A (ja) 2012-03-15
RU2016141576A (ru) 2018-05-03
ECSP045445A (es) 2005-01-28
CY1117973T1 (el) 2017-05-17
SG187991A1 (en) 2013-03-28
US9351986B2 (en) 2016-05-31
FR17C1054I2 (fr) 2019-01-11
JP5153057B2 (ja) 2013-02-27
CN100482277C (zh) 2009-04-29
PL413302A1 (pl) 2016-05-23
ZA200409752B (en) 2010-08-25
PL410219A1 (pl) 2015-03-30
EP3127553B1 (en) 2021-12-01
US20180339058A1 (en) 2018-11-29
EP3127553A1 (en) 2017-02-08
CN1665532A (zh) 2005-09-07
PT2371392E (pt) 2015-10-07
CY2017035I1 (el) 2018-04-04
EP2371392B1 (en) 2015-07-08
TWI379693B (en) 2012-12-21
DK2371392T3 (en) 2015-08-31
DK1507556T3 (en) 2016-09-12
WO2003092623A2 (en) 2003-11-13
RU2004135101A (ru) 2005-06-27
DK3127553T3 (da) 2022-01-31
BR122019027966B8 (pt) 2021-07-27
HUE030806T2 (hu) 2017-05-29
FR17C1054I1 (OSRAM) 2018-01-12
LT3127553T (lt) 2022-04-11
CA2871117A1 (en) 2003-11-13
KR101125524B1 (ko) 2012-03-22
SG165158A1 (en) 2010-10-28
UA88599C2 (ru) 2009-11-10
PH12013501158B1 (en) 2015-11-09
JP2017105801A (ja) 2017-06-15
HUE057124T2 (hu) 2022-04-28
CR20130390A (es) 2013-11-08
EP1507556A2 (en) 2005-02-23
ES2545745T3 (es) 2015-09-15
HUE027590T2 (hu) 2016-11-28
NO20161431A1 (no) 2005-01-25
CA2483552A1 (en) 2003-11-13
ES2916174T3 (es) 2022-06-28
CR7557A (es) 2008-10-03
PL224001B1 (pl) 2016-11-30
HUS1700038I1 (hu) 2017-11-28
PL374523A1 (en) 2005-10-31
HK1070825A1 (en) 2005-06-30
RU2422157C3 (ru) 2021-04-23
RU2602878C3 (ru) 2021-11-24
PL410218A1 (pl) 2015-03-30
BR122019027974B1 (pt) 2022-06-14
CY1116634T1 (el) 2017-03-15
WO2003092623A3 (en) 2004-03-18
MXPA04010792A (es) 2005-03-07
PH12013501159A1 (en) 2015-12-02
PT3127553T (pt) 2022-01-24
NZ586071A (en) 2012-02-24
LUC00044I1 (OSRAM) 2017-11-03
RU2016141576A3 (OSRAM) 2018-05-03
KR101062628B1 (ko) 2011-09-07

Similar Documents

Publication Publication Date Title
NO339730B1 (no) Et monomer calicheamicin derivat/anti-CD22 antistoff konjugat samt anvendelse derav.
AU2017204487B2 (en) Calicheamicin derivative-carrier conjugates
AU2012244218C1 (en) Calicheamicin derivative-carrier conjugates
HK1233519B (en) Calicheamicin derivative-carrier conjugates
HK1233519A1 (en) Calicheamicin derivative-carrier conjugates
HK1233519A (en) Calicheamicin derivative-carrier conjugates
HK1162926B (en) Calicheamicin derivative-carrier conjugates
HK1070825B (en) Calicheamicin derivative-carrier conjugates

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: WYETH HOLDINGS LLC, US

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170713

Spc suppl protection certif: 2017061

Filing date: 20171121

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170713

Spc suppl protection certif: 2017061

Filing date: 20171121

Extension date: 20280502

MK1K Patent expired
SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: WYETH HOLDINGS LLC, US

Spc suppl protection certif: 2017061

SPCT Change of name or address of the representative of a supplementary protection certificate

Spc suppl protection certif: 2017061

Representative=s name: ZACCO NORWAY AS, NORGE